Clinical Perspectives for the Use of Melatonin as a Chronobiotic and Cytoprotective Agent
- 1 December 2005
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1057 (1) , 327-336
Abstract
The circadian time system involves periodic gene expression at the cellular level, synchronized by a hierarchically superior structure located in the hypothalamic suprachiasmatic nuclei. Treatment of circadian rhythm disorders has led to the development of a new type of agent called "chronobiotics," among which melatonin is the prototype. In elderly insomniacs, melatonin treatment decreased sleep latency and increased sleep efficiency, particularly slow-wave sleep. The effect of melatonin on sleep is the consequence of increasing sleep propensity (by augmenting the amplitude of circadian clock oscillation via MT1 receptors) and of synchronizing the circadian clock via MT2 receptors. Daily melatonin production decreases with age and in several pathologies, attaining its lowest values in Alzheimer's disease (AD) patients. About 45% of AD patients have disruptions in their sleep and "sundowning" agitation. Generally, melatonin treatment decreases sundowning in AD patients and reduced variability of sleep onset time. Both open and controlled studies have indicated a significant decrease of cognitive deterioration in AD patients treated with melatonin. The mechanisms accounting for the possible therapeutic effect of melatonin in AD patients may be manifold. On one hand, melatonin treatment promotes slow-wave sleep in the elderly and could be beneficial by augmenting the restorative phases of sleep. On the other hand, melatonin protects neurons against beta-amyloid toxicity. By its combined chronobiotic and cytoprotective properties melatonin provides an innovative neuroprotective strategy to reduce the cost of lifetime treatment of some neuropsychiatric disorders.Keywords
This publication has 77 references indexed in Scilit:
- Melatonin Treatment of Day-Night Rhythm Disturbances and Sundowning in Alzheimer DiseaseJournal of Clinical Psychopharmacology, 2004
- Melatonin and mitochondrial functionLife Sciences, 2004
- Effect of melatonin on vascular reactivity in pancreatectomized ratsLife Sciences, 2004
- Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travelJournal of Applied Physiology, 2004
- Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in n1e-115 cellsExperimental Neurology, 2003
- Astrocytes contribute to neuronal impairment in βA toxicity increasing apoptosis in rat hippocampal neuronsGlia, 2001
- Melatonin reduces interleukin secretion in amyloid-β stressed mouse brain slicesChemico-Biological Interactions, 2001
- Treatment of sleep disturbance in Alzheimer's diseaseSleep Medicine Reviews, 2000
- An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's diseaseJournal of Neural Transmission, 2000
- Modulation of the subcellular distribution of calmodulin by melatonin in MDCK cellsJournal of Pineal Research, 1998